Nanocolloidosomes with Selective Drug Release for Active Tumor-Targeted Imaging-Guided Photothermal/Chemo Combination Therapy

ACS Appl Mater Interfaces. 2017 Dec 6;9(48):42225-42238. doi: 10.1021/acsami.7b14796. Epub 2017 Nov 20.

Abstract

Selective drug release is highly desirable for photothermal/chemo combination therapy when two or even more theranostic agents are encapsulated together within the same nanocarrier. A conventional nanocarrier can hardly achieve this goal. Herein, doxorubicin and indocyanine green (DOX/ICG)-loaded nanocolloidosomes (NCs), with selective drug release, were fabricated as a novel multifunctional theranostic nanoplatform for photothermal/chemo combination therapy. Templating from galactose-functionalized hydroxyethyl starch-polycaprolactone (Gal-HES-PCL) nanoparticles-stabilized Pickering emulsions, the resultant DOX/ICG@Gal-HES-PCL NCs had a diameter of around 140 nm and showed an outstanding tumor-targeting ability, preferable tumor penetration capability, and promotion of photothermal effect. Moreover, these NCs can be used for NIR fluorescence imaging and thus render real-time imaging of solid tumors with high contrast. Collectively, such NCs achieved the best in vivo antitumor efficacy combined with laser irradiation compared with DOX/ICG@HES-PCL NCs and DOX/ICG mixture. These NCs are valuable for active tumor-targeted imaging-guided combination therapy against liver cancer and potentially other diseases.

Keywords: active targeting; hydroxyethyl starch; nanocolloidosomes; photothermal/chemo combination therapy; selective drug release.

MeSH terms

  • Combined Modality Therapy
  • Doxorubicin
  • Drug Liberation
  • Humans
  • Hyperthermia, Induced
  • Neoplasms
  • Photochemical Processes*
  • Phototherapy

Substances

  • Doxorubicin